- Report
- August 2024
Japan, United States, ... Japan, United States, Europe
From €3340EUR$3,500USD£2,799GBP
- Report
- November 2023
- 238 Pages
Global
€4767EUR$4,995USD£3,994GBP
- Report
- July 2024
- 83 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2024
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- April 2022
Japan, United States, ... Japan, United States, Europe, Global
From €2625EUR$2,750USD£2,199GBP
- Report
- December 2021
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- November 2024
Japan, United States, ... Japan, United States, Europe, Global
From €4295EUR$4,500USD£3,598GBP
The Toxoplasmosis Test is a type of Infectious Disease Testing used to detect the presence of the parasite Toxoplasma gondii in a patient's blood. It is used to diagnose toxoplasmosis, an infection caused by the parasite, which can cause serious health problems in pregnant women and those with weakened immune systems. The test is typically performed using a blood sample, which is then tested for the presence of antibodies to the parasite. If antibodies are present, it indicates that the patient has been infected with the parasite.
The Toxoplasmosis Test market is a subset of the larger Infectious Disease Testing market, which is estimated to be worth billions of dollars. The market is expected to grow in the coming years due to the increasing prevalence of infectious diseases, as well as the development of new technologies and tests.
Some companies in the Toxoplasmosis Test market include Abbott Laboratories, Becton Dickinson, Bio-Rad Laboratories, Cepheid, and DiaSorin. Show Less Read more